-+ 0.00%
-+ 0.00%
-+ 0.00%
Citibank: Raising the target price of Medicinal Kangde (02359) to HK$240 to maintain a “buy” rating
Share
Listen to the news

The Zhitong Finance App learned that Citi released a research report stating that it raised Yao Ming Kangde (02359)'s 2026-2028 revenue forecast by 2%, 8% and 11%, respectively, and the earnings forecast per share was raised by 10%, 5% and 9% respectively; the target price was raised from HK$215 to HK$240, maintaining a “buy” rating.

Yao Ming Kangde's management raised its guidance for the 2026 fiscal year. The total revenue forecast was raised from RMB 58.5 billion to RMB 60.5 billion to RMB 61 billion to RMB 61.9 billion; revenue from continuing operations is expected to increase 40% to 42% year-on-year, compared to 35% to 39% previously. Furthermore, despite facing new production capacity increases and foreign exchange headwinds, the company maintained a stable and resilient adjusted non-IFRS net interest rate this year.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending